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Continuous manufacturing is a relevant trend in biopharmaceutical production to reduce the process footprint 
and to improve the process economy. Vaccines against world-spread diseases, such as influenza, should 
benefit in particular from such an approach, given the increasing demand for seasonal vaccines and the need 
for a fast response in case of a pandemic outbreak. Upstream processing of viral vaccines has seen important 
progress in continuous production of viral vaccines [1], which further supports the development of hybrid or fully 
continuous flow-schemes for downstream processing. 
 
In this work, we implemented a multi-column strategy for the chromatographic purification of a continuous feed 
stream of cell culture-derived influenza A virus particles using sulfated cellulose membrane adsorbers (SCMA). 
The use of SCMA for batch purification of influenza A virus particles is well described [2] as well as the process 
conditions required for a successful separation [3]. This facilitated the transfer of this chromatography technique 
from batch to continuous-mode. Using a 3-device set-up, we reproducibly purified cell-culture derived influenza 
A/Puerto Rico/8/1934 virus particles during 10 cycles. Each cycle comprised load, wash, elution and re-
equilibration of all three devices. The virus hemagglutinin 
activity (HA) average yield obtained was 67% ± 11%, 
with contaminant removals above 70% for total protein 
and 99.8% for DNA, respectively. Moreover, the 
contaminant content relative to the eluted HA were  
1.0 ± 0.1 µgtotal protein/kHAU and  
3.5 ± 0.7 ngDNA/kHAU. These are similar to those 
achieved for comparable batch runs. In addition, based 
on the breakthrough curves [Fig. 1], the SCMA were 
challenged to about 69% of their estimated static binding 
capacity. Compared to traditional batch operation 
(capacity challenge at 70% of the dynamic binding 
capacity, DBC10%), continuous operation of the SCMA 
saves at least 10% of the processing time. 
Overall, the implementation of this continuous 
chromatography approach for the purification of viral 
particles would result in a considerable reduction of plant 
footprint, buffer consumption, and operating costs. Yields 
and contamination levels achieved support the future use 
of membrane chromatography as a platform solution, 
especially suited for low-cost vaccine manufacturing. 
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Figure 1 – A continuous multi-column strategy for 
the purification of influenza A virus using SCMA 
increases to overall capacity used per device (k2), in 
comparison to the traditional capacity challenge 
used in batch mode (k1). The virus particles loss on 
the flow through of the main load device are caught 
by the following device (k3). 
